Alliance Global Partners analyst Matthew Venezia initiated coverage of Cibus with a Buy rating and $25 price target. Cibus is an agricultural biotechnology company that is focused on developing agronomically important traits in the world’s most widely grown crops, the analyst tells investors in a research note. The firm says the company is positioned as a trait developer, using a unique method of crop improvement to improve qualities of crops such as resistance to disease and tolerance to herbicides. It anticipates Cibus to have its first year of profitability in 2028.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBUS:
- Cibus assumed with a Buy at Canaccord
- Cibus Expands its Intellectual Property Coverage for Plant Gene Editing and Traits
- Cibus expands intellectual property coverage for plant gene editing, traits
- Cibus confirms edits in Canola for initial Nutrient Use Efficiency trait
- Cibus to Participate in Upcoming June Investor Events